{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.3","upperLimit":"85.3","value":"40.0"},{"groupId":"OG001","lowerLimit":"22.3","upperLimit":"95.7","value":"66.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"CR rate is defined as the percentage of participants with CR according to the Modified Lugano Criteria for Response Assessment (Cheson 2014).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with classic Hodgkin lymphoma","id":"OG000","title":"Classic Hodgkin Lymphoma"},{"description":"Participants with peripheral T cell lymphoma","id":"OG001","title":"PTCL"}],"paramType":"NUMBER","populationDescription":"The full analysis set includes participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Up to 18.3 months","title":"Rate of Complete Response Per Investigator Assessment According to Modified Lugano Response Criteria","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}